Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
المؤلفون المشاركون
Coate, Bruce
Kakuda, Thomas
Vis, Peter
Sekar, Vanitha
Anderson, David
Mrus, Joseph
De La Rosa, Guy
Ryan, Robert
المصدر
العدد
المجلد 2012، العدد 2012 (31 ديسمبر/كانون الأول 2012)، ص ص. 1-10، 10ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2012-03-21
دولة النشر
مصر
عدد الصفحات
10
التخصصات الرئيسية
الملخص EN
Objectives.
Evaluation of pharmacokinetics and pharmacodynamics of darunavir and etravirine among HIV-1–infected, treatment-experienced adults from GRACE, by sex and race.
Methods.
Patients received darunavir/ritonavir 600/100mg twice daily plus other antiretrovirals, which could include etravirine 200mg twice daily.
Population pharmacokinetics for darunavir and etravirine were determined over 48 weeks and relationships assessed with virologic response and safety.
Rich sampling for darunavir, etravirine, and ritonavir was collected in a substudy at weeks 4, 24, and 48.
Results.
Pharmacokinetics were estimated in 376 patients for darunavir and 190 patients for etravirine.
Median darunavir AUC12h and C0h were 60,642ng·h/mL and 3624ng/mL, respectively; and for etravirine were 4183ng · h/mL and 280ng/mL, respectively.
There were no differences in darunavir or etravirine AUC12h or C0h by sex or race.
Age, body weight, or use of etravirine did not affect darunavir exposure.
No relationships were seen between darunavir pharmacokinetics and efficacy or safety.
Patients with etravirine exposure in the lowest quartile generally had lower response rates.
Rich sampling showed no time-dependent relationship for darunavir, etravirine, or ritonavir exposure over 48 weeks.
Conclusions.
Population pharmacokinetics showed no relevant differences in darunavir or etravirine exposure by assessed covariates.
Lower etravirine exposures were associated with lower response rates.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Kakuda, Thomas& Sekar, Vanitha& Vis, Peter& Coate, Bruce& Ryan, Robert& Anderson, David…[et al.]. 2012. Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. AIDS Research and Treatment،Vol. 2012, no. 2012, pp.1-10.
https://search.emarefa.net/detail/BIM-452937
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Kakuda, Thomas…[et al.]. Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. AIDS Research and Treatment No. 2012 (2012), pp.1-10.
https://search.emarefa.net/detail/BIM-452937
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Kakuda, Thomas& Sekar, Vanitha& Vis, Peter& Coate, Bruce& Ryan, Robert& Anderson, David…[et al.]. Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. AIDS Research and Treatment. 2012. Vol. 2012, no. 2012, pp.1-10.
https://search.emarefa.net/detail/BIM-452937
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-452937
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر